These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9537918)

  • 21. The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia.
    Pecorelli S;
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):13-5. PubMed ID: 12082648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 23. Should all patients with chronic kidney disease receive an EPO-type drug?
    Berns JS
    Cleve Clin J Med; 2006 Mar; 73(3):298-300. PubMed ID: 16548453
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    VanAudenrode M
    J Natl Cancer Inst; 2003 May; 95(10):761-2; author reply 762-3. PubMed ID: 12759400
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy.
    Littlewood TJ
    Front Radiat Ther Oncol; 2002; 37():34-7. PubMed ID: 11764665
    [No Abstract]   [Full Text] [Related]  

  • 26. Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy".
    Nowrousian MR
    Oncologist; 2006 May; 11(5):535-6; author reply 536-7. PubMed ID: 16720859
    [No Abstract]   [Full Text] [Related]  

  • 27. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Waltzman RJ
    Cancer; 2004 Apr; 100(7):1545-6; author reply 1546. PubMed ID: 15042691
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of epoetin in chronic renal failure.
    Coyne DW
    JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
    [No Abstract]   [Full Text] [Related]  

  • 29. Racial differences in erythropoietin responsiveness.
    Kaufman JS
    Am J Kidney Dis; 2008 Dec; 52(6):1035-8. PubMed ID: 19026356
    [No Abstract]   [Full Text] [Related]  

  • 30. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeted molecular mechanisms of epoetin alfa.
    Langer CJ; Hirsch FR; Cortés-Funes H; Sawyer ST; Thatcher N
    Lung Cancer; 2003 Aug; 41 Suppl 1():S133-45. PubMed ID: 12867072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epoetin dosing and dialysis facility ownership.
    Kliger AS; Nissenson AR
    JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
    [No Abstract]   [Full Text] [Related]  

  • 33. Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis.
    Jones M; Schenkel B; Just J; Fallowfield L
    Cancer; 2004 Oct; 101(8):1720-32. PubMed ID: 15386341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in quality of life for cancer patients treated with epoetin alfa.
    Libretto SE; Barrett-Lee PJ; Branson K; Gorst DW; Kaczmarski R; McAdam K; Stevenson P; Thomas R
    Eur J Cancer Care (Engl); 2001 Sep; 10(3):183-91. PubMed ID: 11829381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
    Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
    J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early epoetin alfa treatment in children with solid tumors.
    Zoubek A; Kronberger M
    Med Pediatr Oncol; 2002 Oct; 39(4):459-62. PubMed ID: 12203664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human erythropoietin in pediatric oncology: a review.
    Feusner J; Hastings C
    Med Pediatr Oncol; 2002 Oct; 39(4):463-8. PubMed ID: 12203665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epoetin alfa: to give or not to give.
    Dang C; Hudis C; Norton L
    J Natl Cancer Inst; 2013 Jul; 105(14):1001-3. PubMed ID: 23860203
    [No Abstract]   [Full Text] [Related]  

  • 40. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.